Khiron Life Sciences (STU:4KH) Total Operating Expense: €16.90 Mil (TTM As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Khiron Life Sciences Total Operating Expense?

Khiron Life Sciences STU:4KH Total Operating Expense is €16.90 Mil as of Sep. 2022.

Khiron Life Sciences's Total Operating Expense for the three months ended in Sep. 2022 was €3.91 Mil. Khiron Life Sciences's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2022 was €16.90 Mil.

Khiron Life Sciences Total Operating Expense Related Terms

Khiron Life Sciences Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Khiron Life Sciences's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Khiron Life Sciences Total Operating Expense Chart

Khiron Life Sciences Annual Data
Trend May12 May13 May14 May15 May16 May17 Dec18 Dec19 Dec20 Dec21
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 12.42 27.35 19.65 18.09

Khiron Life Sciences Quarterly Data
Nov17 Feb18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.30 4.28 4.67 4.04 3.91

Khiron Life Sciences Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €16.90 Mil mean?
Khiron Life Sciences (STU:4KH) has a Total Operating Expense of €16.90 Mil as of Sep. 2022. Total operating expense is the primary recurring expense associated with central operations. View historical data on Khiron Life Sciences and its competitors.
Is Khiron Life Sciences' Total Operating Expense too high?
Khiron Life Sciences' current Total Operating Expense is €16.90 Mil.
How does Khiron Life Sciences' Total Operating Expense compare to ZTS and CTLT?
Khiron Life Sciences' Total Operating Expense of €16.90 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Khiron Life Sciences and its competitors. Khiron Life Sciences's current Total Operating Expense is €16.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Khiron Life Sciences stock overvalued right now?
Khiron Life Sciences (STU:4KH) has a current Total Operating Expense of €16.90 Mil. The current Total Operating Expense is €16.90 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Khiron Life Sciences (STU:4KH), the current Total Operating Expense is €16.90 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Khiron Life Sciences Business Description

Address 2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5
Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.